Vita Coco Hits Record as Insiders Cash Out $18M

NEW YORK, April 30 —

The Vita Coco Company filed its Q1 8-K on April 29. Net income rose, net sales rose, and management lifted its 2026 sales outlook. Shares hit an all-time high. BofA raised its price target to $72. The coconut water story finally looked like the consumer-staple breakout bulls have pitched for years. Meanwhile, the people running the company have sold about $18 million of stock into the rally over the last six weeks.

What the Tape Saw

The Q1 release delivered what the bulls ordered. Net income up. Net sales up. Management raised its 2026 sales outlook. Yahoo and Zacks both flagged beats on key metrics versus consensus. Shares opened higher pre-market and ran to a record. BofA's $72 target sits above the $66.95 close, and the rally now has a fresh analyst number behind it.

Coconut water has moved from health-food curiosity to mainstream beverage shelf-anchor. Vita Coco has the brand, the distribution and the operating leverage. The narrative writes itself.

The Form 4s Tell a Different Story

CEO Martin Roper sold 25,000 shares on each of April 7, 8, 10, 14, 15, 16, 24 and 27, plus a 4,456-share clip on April 13. Every sale priced between $50.00 and $50.95. April proceeds: about $10.25M. Each sale was paired with a same-day option exercise at a $10.18 strike for the matching share count — exercise and sell, not a one-off liquidation.

That is how a CEO converts deep-in-the-money options into cash on a metronome. The economics work: Roper bought stock at $10.18 and sold the same day around $50, banking the spread eight times in three weeks. The optics are the problem. Selling at $50 looks fine when the stock is at $50. It looks different when, days later, the stock prints $66.95 on an earnings beat the CEO knew was coming.

He was not alone. COO Jonathan Burth sold 60,000 shares on March 16 between $57.98 and $60.00 for about $3.52M, with 40,000 of those paired with the same $10.18-strike exercises. Executive Chairman Michael Kirban sold 50,000 shares on March 11 and 12 at a flat $58.00 for $2.90M. CFO Corey Baker ran a steady drip — five 2,000-share open-market sales between March 13 and March 19 at $55.45 to $59.92. Director Kenneth Sadowsky and CCO Charles Van each took partial chips off the table at similar levels.

The total: $0 in purchases against $18.48M in sales. The C-suite, the chairman, the CFO and a director are all on the same side of the trade.

The 10b5-1 Defense and Why It Matters Less Than It Sounds

The identically-sized April clips from Roper carry the hallmark of a Rule 10b5-1 plan — pre-scheduled trades that insulate executives from accusations of trading on material non-public information. A 40,000-share Rule 144 sale notice was reported separately in connection with the name. These plans are legal, common, and the responsible way for executives with concentrated stock to diversify.

That does not make them uninformative. Executives choose when to adopt and adjust 10b5-1 plans. Locking in sales at $50 ahead of a quarter management knew was strong is a decision about how much upside is worth waiting for. The plan is the alibi. The decision to start it is the signal.

Why the Multiple Matters

At $66.95, COCO trades at roughly 35x forward earnings on trailing revenue growth of 0.4%. Gross margin is 36.5% — respectable for a beverage business, but not the structural moat that justifies a quality-compounder multiple on its own. The Q1 outlook bump is real. But the price is asking for more than a single guide raise. It is asking for that growth to compound for several years.

The bulls have BofA, an earnings beat, and a brand finally getting its moment. The bears have a flat-revenue trailing year, a 35x multiple, and the people who built the company selling into the strength. Both sides are reading the same Form 4s.

What to Watch

The next checkpoint is the May 22 annual meeting, set up by the DEF 14A and the supplemental DEFA14A filings on April 22 and 23. Then watch the next round of Form 4s. If Roper keeps clipping at $66 the way he clipped at $50, the programmatic-plan defense holds. If selling pauses or accelerates, the read changes. The thesis is neutral with medium confidence: fundamentals support the rally, but a 35x multiple on 0.4% growth, paired with $18M of insider exit, is not a setup to chase. Wait for the next print, or wait for an insider buy. Both are more informative than the current tape.

Run the free The Vita Coco Company, Inc. deep-dive →

Basis Report does not hold positions in securities discussed. This is not investment advice.

Frequently Asked Questions

Why are Vita Coco insiders selling stock?

CEO Martin Roper, COO Jonathan Burth, Executive Chairman Michael Kirban and CFO Corey Baker collectively sold about $18.48M of COCO stock since mid-March. Roper's April sales were paired with same-day $10.18-strike option exercises, consistent with a programmatic plan, as detailed in the Form 4 analysis above.

What did Vita Coco report in Q1?

Vita Coco reported rising net income and net sales and lifted its 2026 sales outlook. Yahoo and Zacks coverage noted beats on key metrics, and shares climbed to an all-time high after the release.

What is BofA's price target on COCO?

BofA raised its price target on Vita Coco to $72, citing strong sales. Against a recent close of $66.95, that implies modest upside from already-record levels.

How much did the Vita Coco CEO sell in April?

CEO Martin Roper sold roughly $10.25M of stock across nine April Form 4 filings, all at prices between $50.00 and $50.95 and each paired with a same-day option exercise at a $10.18 strike.

Is Vita Coco stock expensive?

COCO trades around 35x forward earnings with a $3.82B market cap on $0.61B of trailing revenue that grew just 0.4%. The article above lays out why that multiple, paired with insider selling, argues for caution rather than chasing the all-time high.